Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: sitagliptin


Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19

September 30th 2020

In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment (Diabetes Care)

Categories: Medication, News
Tags: COVID-19, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: COVID-19, sitagliptin, Type 2 Diabetes

Comparative effectiveness of gliclazide modified release vs sitagliptin as second‐line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes

August 9th 2020

In this real‐world study, second‐line gliclazide MR was more effective than sitagliptin in reducing HbA1c, with similar durability and persistence and low rates of hypoglycaemic events, in individuals with type 2 diabetes on metformin treatment and HbA1c above the target of 7.0% (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: gliclazide, metformin, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: gliclazide, metformin, sitagliptin, Type 2 Diabetes

Impact of sitagliptin on endometrial mesenchymal stem-like progenitor cells: A randomised, double-blind placebo-controlled feasibility trial

January 10th 2020

Sitagliptin increases eMSCs and decreases decidual senescence. A large-scale clinical trial evaluating the impact of preconception sitagliptin treatment on pregnancy outcome in RPL is feasible and warranted (EBioMedicine)

Categories: Medication, News
Tags: miscarriage, sitagliptin

Categories: Medication
Tags: miscarriage, sitagliptin

Costarting sitagliptin with metformin is associated with a lower likelihood of disease progression in newly treated people with type 2 diabetes: a cohort study

October 17th 2019

Costarting drug therapy with sitagliptin and metformin was associated with a lower likelihood of disease progression in people with type 2 diabetes compared with adding sitagliptin later (Diabetic Medicine)

Categories: Medication, News
Tags: metformin, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: metformin, sitagliptin, Type 2 Diabetes

Effects of sitagliptin on gastric emptying of, and the glycaemic and blood pressure responses to, a carbohydrate meal in type 2 diabetes

August 30th 2019

In type 2 diabetes, while sitagliptin has no effect on either gastric emptying or postprandial blood pressure, it’s effects to lower postprandial glucose is dependent on the basal rate of gastric emptying (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: gastric emptying, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: gastric emptying, sitagliptin, Type 2 Diabetes

Investigating optimal β‐cell‐preserving treatment in latent autoimmune diabetes in adults: Results from a 21‐month randomized trial

June 20th 2019

β‐cell function after intervention was similar in patients with insulin‐ and sitagliptin‐treated LADA, regardless of the strength of autoimmunity. Further, participants with low levels of GAD antibodies did not experience progressive deterioration of β‐cell function over a 21‐month period. Taken together, these findings could be useful for clinicians’ choices of treatment in people with LADA (Diabetes, Obesity and Metabolism)

Categories: News, Treatment
Tags: B Cell, insulin, lada, sitagliptin

Categories: Treatment
Tags: B Cell, insulin, lada, sitagliptin

Cost‐effectiveness of intensification with sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom

April 1st 2019

or UK patients with T2D not at goal on metformin and sitagliptin therapy, treatment intensification with SGLT2 inhibitors prior to NPH insulin is cost‐neutral or cost‐effective compared with immediate NPH insulin intensification (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: metformin, SGLT2 inhibitors, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: metformin, SGLT2 inhibitors, sitagliptin, Type 2 Diabetes

Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes

April 1st 2019

When initiating insulin glargine therapy, continuation of sitagliptin, compared with discontinuation, resulted in a clinically meaningful greater reduction in HbA1c without an increase in hypoglycaemia (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: HbA1c, hypoglycemia, insulin, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: HbA1c, hypoglycemia, insulin, sitagliptin, Type 2 Diabetes

Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea

March 23rd 2019

Among adults with type 2 diabetes uncontrolled with metformin with or without sulfonylurea, oral semaglutide, 7 mg/d and 14 mg/d, compared with sitagliptin, resulted in significantly greater reductions in HbA1c over 26 weeks, but there was no significant benefit with the 3-mg/d dosage. Further research is needed to assess effectiveness in a clinical setting (JAMA)

Categories: Medication, News
Tags: semaglutide, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: semaglutide, sitagliptin, Type 2 Diabetes

Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT‐M study

March 18th 2019

In participants not at HbA1c goal on a sub‐maximal dose of metformin, addition of sitagliptin at the time of metformin dose uptitration improved glycaemic response and HbA1c goal attainment, with similar safety and tolerability, compared to metformin uptitration alone (Diabetes, Obesity and Metabolism)

Categories: News, Treatment
Tags: metformin, sitagliptin, Type 2 Diabetes

Categories: Treatment
Tags: metformin, sitagliptin, Type 2 Diabetes

Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin up‐titration in treatment of patients with type 2 diabetes: the CompoSIT‐M Study

January 6th 2019

In participants not at HbA1c goal on a sub‐maximal dose of metformin, addition of sitagliptin at the time of metformin dose up‐titration improved glycemic response and HbA1c goal attainment with similar safety and tolerability compared to metformin up‐titration alone (Diabetes, Obesity and Metabolism)

Categories: News, Treatment
Tags: HbA1c, metformin, sitagliptin

Categories: Treatment
Tags: HbA1c, metformin, sitagliptin

Analysis of the effect of seasonal administration on efficacy of sitagliptin: subanalysis of the JAMPstudy

February 15th 2018

This study suggested that the season of administration of sitagliptin influenced subsequent hypoglycemic effect even after analysis excluding the influence of HbA1c value at the start of treatment. This study provides possibility, indicating that seasonal fluctuations have an effect on the efficacy of antidiabetic drugs (Journal of Diabetes Investigation)

Categories: Medication, News
Tags: seasonal, sitagliptin

Categories: Medication
Tags: seasonal, sitagliptin

Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)

September 21st 2017

The present pilot trial suggests that treatment of SPIDDM/LADA by sitagliptin, a DPP-4 inhibitor, may be more effective in preserving the β-cell function than insulin treatment for at least 4 years, possibly through the immune modulatory effects of DPP-4 inhibitors (Diabetes Therapy)

Categories: Medication, News
Tags: DPP-4 inhibitors, sitagliptin, Type 1 Diabetes

Categories: Medication
Tags: DPP-4 inhibitors, sitagliptin, Type 1 Diabetes

Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study

May 11th 2017

Adding sitagliptin to conventional antidiabetic regimens in patients with T2DM for 24 months attenuated the annual exacerbation in the echocardiographic parameter of diastolic dysfunction (E/e′) independent of other clinical variables such as blood pressure and glycemic control (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: sitagliptin, Type 2 Diabetes

Categories: Cardiovascular
Tags: sitagliptin, Type 2 Diabetes

Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study

February 16th 2017

This study demonstrated that exenatide QWS-AI reduced HbA1c more than sitagliptin or placebo and was well tolerated (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: exenatide, metformin, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: exenatide, metformin, sitagliptin, Type 2 Diabetes

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial

December 28th 2016

A 12-week treatment with liraglutide or sitagliptin only resulted in a brief and modest increase of plasma pancreatic enzyme concentrations in patients with type 2 diabetes. Apart from a minimal sitagliptin-induced increase in intraduodenal fluid secretion, pancreatic exocrine function was unaffected (Diabetes Care)

Categories: Medication, News
Tags: liraglutide, Pancreas, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: liraglutide, Pancreas, sitagliptin, Type 2 Diabetes

Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs

December 2nd 2016

Sitagliptin improved the HbA1c level and rate of achieving the target control levels in patients with type 2 diabetes mellitus who were previously untreated with, or poorly responsive to, existing antidiabetic drugs. Thus, sitagliptin is expected to be useful in this patient group (BMC Endocrine Disorders)

Categories: Medication, News
Tags: sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: sitagliptin, Type 2 Diabetes

Adherence, persistence, and treatment discontinuation with sitagliptin compared to sulfonylureas as add-ons to metformin

August 18th 2016

SITA (vs. SU) + MET users had significantly higher mean PDC, adherence, and persistence. These trends were robust to model alterations and were more marked when accommodating OPEs  (Journal of Diabetes)

Categories: Medication, News
Tags: sitagliptin, sulfonylureas

Categories: Medication
Tags: sitagliptin, sulfonylureas

Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: a real-world evidence study

May 18th 2016

Our results suggest that both sitagliptin and SU reduce albuminuria as an add-on therapy to metformin, but that sitagliptin may provide greater reductions in albuminuria independent of glycemic control when compared to SU. Larger population studies are required to further explore this (Diabetes and Its Complications)

Categories: Nephrology, News
Tags: albuminuria, sitagliptin, sulfonylureas, Type 2 Diabetes

Categories: Nephrology
Tags: albuminuria, sitagliptin, sulfonylureas, Type 2 Diabetes

Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs

April 26th 2016

In this large cohort study, a higher risk for hHF was not observed in users of saxagliptin or sitagliptin compared with other selected antihyperglycemic agents (Annals of Internal Medicine)

Categories: Medication, News
Tags: saxagliptin, sitagliptin

Categories: Medication
Tags: saxagliptin, sitagliptin
  • 1
  • 2
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Novo NordiskAstraZenecaNapp Diabetes

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes CareAbout Ascensia Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 elderly Empagliflozin exenatide exercise GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership